mmu-mir-455: Mmu-mir-455 is a microRNA that has been found to be elevated in so-stimulated CM EXOs and is involved in preventing the activation of matrix metalloproteinase 9 (MMP9), which helps preserve the heart from fibrosis and myocyte uncoupling [PMC6406975]. In a study involving mice, different groups were injected with mmu-mir-455 agomir, mmu-miR-210 agomir, or control agomir, and it was found that the mmu-mir-455 agomir group had higher cartilage OARSI grade scores and collagen II content compared to the control group [PMC7658376]. Mmu-mir-455 has been identified as a precursor miRNA [PMC4356433]. In another study, it was found that mmu-miR-29c at ST and LT did not show identical regulation as observed with microarray profiling, but mmu-mir-455 at LT and mmu-miR-450a at IT did show similar regulation [PMC3030602]. Mmu-mir-455 has been selected based on its high and significant differential expression in a lung pathology model [PMC3030602]. The expression of mmu-mir-455 was first documented in miRBase v8.1 [PMC3125744]. TaqMan RT-PCR assays were used to assess the expression of mmu-mir-455 in mice [PMC4386824]. The miRNA–messenger RNA regulatory networks revealed common target genes between mmu-miR-181d and mmu-mir-455 (MOSPD1), between mmu-miR31 and mmu miR182 (TAF4A), between between between between between between (RTN4), between (BDNF), between between between (PPP1R10), and between (LRRC1) [PMC3742134].